Aziyo Biologics, Inc. AZYO
We take great care to ensure that the data presented and summarized in this overview for AZIYO BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AZYO
View all-
Nantahala Capital Management, LLC New Canaan, CT3.18MShares$4.62 Million0.19% of portfolio
-
Aigh Capital Management LLC Baltimore, MD3.17MShares$4.59 Million0.76% of portfolio
-
Silverarc Capital Management, LLC2.85MShares$4.13 Million0.85% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.64MShares$3.83 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.37MShares$1.99 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.18MShares$1.71 Million0.0% of portfolio
-
Perkins Capital Management Inc1.13MShares$1.64 Million1.62% of portfolio
-
Knollwood Investment Advisory, LLC Hunt Valley, MD1.03MShares$1.5 Million0.08% of portfolio
-
Birchview Capital, LP Burlington, VT711KShares$1.03 Million0.83% of portfolio
-
Geode Capital Management, LLC Boston, MA255KShares$370,0570.0% of portfolio
Latest Institutional Activity in AZYO
Top Purchases
Top Sells
About AZYO
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Insider Transactions at AZYO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
C Randal Mills PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,664
-2.5%
|
$0
$0.7 P/Share
|
|
Dec 10
2025
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,083
+6.56%
|
-
|
|
Dec 10
2025
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,461
-1.14%
|
$0
$0.7 P/Share
|
|
Dec 10
2025
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+3.09%
|
-
|
|
Dec 10
2025
|
Michelle Le Roux Williams CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,951
-3.73%
|
$0
$0.7 P/Share
|
|
Dec 10
2025
|
Michelle Le Roux Williams CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+10.56%
|
-
|
|
Dec 02
2025
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
5,500
+1.43%
|
$0
$0.67 P/Share
|
|
Dec 01
2025
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
4,500
+1.19%
|
$0
$0.65 P/Share
|
|
Dec 01
2025
|
Guido J Neels |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+8.33%
|
-
|
|
Nov 24
2025
|
C Randal Mills PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.37%
|
$0
$0.6 P/Share
|
|
Nov 17
2025
|
David Colpman |
BUY
Open market or private purchase
|
Direct |
15,500
+45.46%
|
$0
$0.74 P/Share
|
|
Nov 13
2025
|
C Randal Mills PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
13,500
+1.27%
|
$0
$0.75 P/Share
|
|
Sep 10
2025
|
Michelle Le Roux Williams CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,950
-4.06%
|
$3,950
$1.36 P/Share
|
|
Sep 10
2025
|
Michelle Le Roux Williams CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+11.38%
|
-
|
|
Sep 10
2025
|
C Randal Mills PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,664
-2.78%
|
$9,664
$1.36 P/Share
|
|
Sep 10
2025
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,083
+7.22%
|
-
|
|
Sep 10
2025
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,348
-2.73%
|
$10,348
$1.36 P/Share
|
|
Sep 10
2025
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
29,000
+7.1%
|
-
|
|
Jun 21
2025
|
C Randal Mills PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,019
-2.44%
|
$8,019
$1.81 P/Share
|
|
Jun 21
2025
|
C Randal Mills PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,473
+6.39%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 271K shares |
|---|---|
| Open market or private purchase | 884K shares |
| Payment of exercise price or tax liability | 95.9K shares |
|---|